Publications
Detailed Information
Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chun, June Young | - |
dc.contributor.author | Kim, Kichun | - |
dc.contributor.author | Lee, Min Kyeong | - |
dc.contributor.author | Kang, Chang Kyung | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Oh, Myoung-don | - |
dc.date.accessioned | 2021-02-19T04:24:36Z | - |
dc.date.available | 2021-02-19T13:50:10Z | - |
dc.date.issued | 2021-01-26 | - |
dc.identifier.citation | BMC Infectious Diseases. 2021 Jan 26;21(1):117 | ko_KR |
dc.identifier.issn | 1471-2334 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173355 | - |
dc.description.abstract | Background
Herpes zoster (HZ) infection of hematopoietic stem cell transplant (HSCT) patients is of clinical concern. Vaccination could help restore immunity to varicella zoster virus (VZV); however, temporal changes in immunogenicity and safety of live HZ vaccines after HSCT is still unclear. The aim of this study was to elucidate the temporal immunogenicity and safety of the HZ vaccine according to time since HSCT and to determine optimal timing of vaccination. Methods Live HZ vaccine was administered to patients 2–5 years or > 5 years post-HSCT. Control groups comprised patients with a hematologic malignancy who received cytotoxic chemotherapy and healthy volunteers. Humoral and cellular immunogenicity were measured using a glycoprotein enzyme-linked immunosorbent assay (gpELISA) and an interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assay. Vaccine-related adverse events were also monitored. Results Fifty-six patients with hematologic malignancy (41 in the HSCT group and 15 in the chemotherapy group) along with 30 healthy volunteers were enrolled. The geometric mean fold rises (GMFRs) in humoral immune responses of the 2–5 year and > 5 year HSCT groups, and the healthy volunteer group, were comparable and significantly higher than that of the chemotherapy group (3.15, 95% CI [1.96–5.07] vs 5.05, 95% CI [2.50–10.20] vs 2.97, 95% CI [2.30–3.83] vs 1.42, 95% CI [1.08–1.86]). The GMFR of cellular immune responses was highest in the HSCT 2–5 year group and lowest in the chemotherapy group. No subject suffered clinically significant adverse events or reactivation of VZV within the follow-up period. Conclusion Our findings demonstrate that a live HZ vaccine is immunogenic and safe when administered 2 years post-HSCT. | ko_KR |
dc.description.sponsorship | This study was supported by the SNUH Research Fund [grant no 03–2017-0360]. The Funders had no role in study design and collection, analysis or interpretation of the data. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | Herpes zoster | - |
dc.subject | Varicella zoster virus | - |
dc.subject | Hematopoietic stem cell transplantation | - |
dc.subject | Immunogenicity, Safety | - |
dc.title | Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 전준영 | - |
dc.contributor.AlternativeAuthor | 김기천 | - |
dc.contributor.AlternativeAuthor | 이민경 | - |
dc.contributor.AlternativeAuthor | 강창경 | - |
dc.contributor.AlternativeAuthor | 고영일 | - |
dc.contributor.AlternativeAuthor | 신동엽 | - |
dc.contributor.AlternativeAuthor | 홍준식 | - |
dc.contributor.AlternativeAuthor | 최평균 | - |
dc.contributor.AlternativeAuthor | 김남중 | - |
dc.contributor.AlternativeAuthor | 박완범 | - |
dc.contributor.AlternativeAuthor | 김인호 | - |
dc.contributor.AlternativeAuthor | 오명돈 | - |
dc.identifier.doi | 10.1186/s12879-021-05806-4 | - |
dc.citation.journaltitle | BMC Infectious Diseases | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2021-01-27T09:18:16Z | - |
dc.citation.number | 1 | ko_KR |
dc.citation.startpage | 117 | ko_KR |
dc.citation.volume | 21 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.